Another Banner Year

Better Outlook
Boosts Quality of Life

Study Halts Needless Drugs

Clues Lead to More Effective Treatments

Breakthrough in Bladder Cancer

Reducing Nausea in Cancer Treatment

Personalized Medicine, page 12
Real Life Results, page 14
Awards, page 16
Table of contents

12

14

16

6

Personalized Medicine | 21st Century Cancer Care

Real Life Results | A Story of the Impact of Research

Awards | Recognizing Greatness in Others

Read All About Us

22

26

28

Financials | Report from the Auditors

Our Reach

Our Contributors
Caring for patients with cancer continues to challenge us and the reality is there are no cures for many of the conditions we treat. Only with targeted drug discovery can we change this unpleasant fact. This highlights the need for clinical research and makes the case as to why our organization is now more relevant than ever. The advent of new health care reform drastically changes the landscape of cancer care, as well as the roles of large health organizations in providing quality and affordable care. These two facts put the Hoosier Oncology Group at a crossroad, and it is time to rethink our relationships and goals.

Twenty-first century cancer therapy now dictates that instead of a standard treatment used across the same cancer, treatment is now viewed as a pathway to a target and allows us to provide an individualized treatment plan that targets a specific cancer. Every cancer patient will require sophisticated tests that may not be available at their doctor’s office, and our academic partnerships with Indiana University Melvin and Bren Simon Cancer Center and Purdue University will be instrumental in facilitating this testing.

Cancer care delivery is shifting from the traditional office-based model to a health care system model, and Hoosier Oncology will work with these large health care systems to manage clinical trials. One of the biggest implications of this change is that these large health care systems will judge their quality based on developing pathways to manage their patients. Going forward, the default first step for all cancer patients will be screening with sophisticated tests to determine whether or not the patient is a candidate for a clinical trial. Hogg Oncology Group must have a large clinical trial portfolio to offer our patients. These trials will come from different sources, including our academic partners and our scientific colleagues in pharmaceutical and biotechnology companies. I am confident that the Hoosier Oncology Group has the flexibility to meet the challenges of this shifting trend in health care delivery with the quality and expertise for which we are known in the oncology community.

Hogg Oncology Group will continue to serve as the hub for clinical research in Indiana, though these novel trials will require a different level of management and a different source of funding. As part of the shifting currents in oncology, we now must take an active role in helping our investigators find funding for these screening and correlative studies. We need to enhance our philanthropy work and monies should be used to fund highly relevant and competitive trials.

Speaking of philanthropy, I would like to recognize a special friend of the Hoosier Oncology Group, Mrs. Jane Hoeppner. Jane started a fundraising effort called the Coach Hep Indiana Cancer Challenge (CHICC), honoring the memory of her late husband and Indiana University football coach, Terry Hoeppner. This year the CHICC made a very generous donation to facilitate personalized medicine in cancer research. Clearly, with this grant we are one step closer to 21st century research.

In closing, I would like to recognize the Hoosier Oncology Group staff. I cannot imagine a more dedicated and flexible group of enthusiastic individuals than those serving this organization. They have been working hard for one mission despite all the challenges we face in the current economic climate. Their goal is simple, yet great. They want one thing and one thing only – to find the cure for cancer. Thank you for all you do, and I am confident that together we can increase the number and quality of clinical trials offered to our patients to achieve the ultimate goal of curing those who suffer from cancer.

With kind regards,

Rafat Abonour, M.D.
Dear Cancer Fighters,

Hoosier Oncology has concluded one of the best years in its history. Our publication record was one of the strongest in our illustrious past. We had stable financial performance in a tough economy, and we executed very well on our clinical trial performance that moved numerous studies through phase 1 and into phase 2.

Furthermore, our future is very exciting. Hoosier Oncology is focused on two important areas for improvement so we can continue to deliver leading cancer research, close to home.

Hoosier Oncology is dedicated to providing the best research experience for patients and our members, while leading in the placement of very promising research to assure patients have broad access to novel therapies. One of our challenges in these complex economic times is that our members have told us repeatedly that community research is getting tougher every day. With so many patients still lacking therapies that cure, we feel that a cancer clinical trial should be the “standard of care” for patients. To achieve these objectives, Hoosier Oncology is committed to the following:

**Best Fitting Trials**
First, Hoosier Oncology is partnering with the Indiana University Melvin and Bren Simon Cancer Center, other academic networks, and Industry innovators to greatly expand our portfolio of research. We have always had good options in the most common diseases, such as lung, breast, prostate and colorectal cancer. However, as we understand cancer biology at a molecular level, we realize there is not much that is “common” anymore – we need to not only have more, but also the “best fitting”, trials for our specific patient populations. We will make sure Hoosier Oncology offers the breadth of trials to service the vast majority of our community members through our research portfolio.

**Great Site Service**
Second, Hoosier Oncology will partner with members to provide a full menu of community research site management services. As the health care environment changes, we have to be prepared to meet our evolving customer needs. A systems approach to health care is driving consolidation of private practices into hospitals and hospitals into hospital systems. Compliance is getting more and more challenging, while health care provider exposures to non-compliance threats are growing at the same time. Furthermore, performance on clinical trials is actually declining, just at a time when the explosion of new trials demands improved participation for the select patient populations that are eligible. Hoosier Oncology is prepared to provide all the necessary services for our members to conduct compliant, high-performance and cost-effective research.

Hoosier Oncology feels that by offering a broad portfolio and expanded services, the “full service research solution” will accrue tremendous benefits to our community members, our academic researchers, and the patients hopeful for a cure. We will do this through application of best practices, realization of economies of scale, centralization of services and standardization of practices. We want our members to be able to provide their patients the best treatment options for their needs, close to their own home and support network. That is what Hoosier Oncology has always prided itself on. We look forward to continuing to serve that mission in the coming years.

Best,
Quake
Another Banner Year

Hoosier Oncology Group has a proud tradition of excellence in research conduct and outcomes. We present our research findings at oncology conferences and meetings worldwide, and we publish in prominent peer-reviewed journals each year.

At the prestigious American Society of Clinical Oncology (ASCO) annual meeting, Hoosier Oncology was awarded one of the highest presentation honors, called the oral presentation, the past four of five years, which is triple the average acceptance rate of oral presentations.

Hoosier Oncology performance at the annual American Society of Clinical Oncology (ASCO) meeting from 2001 - 2011

- 7 oral presentations; 4 of them within the past 5 years
- 34 poster presentations; over 10 of these were poster discussions
- 14 abstract publications
Our 2011 ASCO Showing

Poster Presentation:
Phase I study of everolimus (RAD001) with intrathecal (IT) and subarachnoid (C) in second line metastatic colorectal cancer (mCRC): Hoosier Oncology Group BR05-102
Download Poster

Poster Presentation:
A phase I study of lonafarnib (LF) in patients with locally advanced and metastatic breast cancer (MBC): Hoosier Oncology Group BRE07-126
Download Poster

Trials in Progress Poster Presentation
PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group GU09-145
Download Poster

Trials in Progress Poster Presentation
Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors: Hoosier Oncology Group GU09-145
Download Poster

Trials in Progress Poster Presentation
Randomized, Double-Blinded, Multicenter, Phase II Study of Pemtrexed, Carboplatin, and Bevacizumab with Erasutinib or Placebo in Chemonaive Patients with Stage IIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116
J. Sharma, Constantan Yiannoutsou, Noah Hahn, Christopher Sweeney.
Download Poster

Abstract:
A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: Hoosier Oncology Group LUN07-130

Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75


Paclitaxel Plus Bevacizumab in Patients with Chemoresistant Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group LUN05-99.
Jalal, Shadia; Bedano, Pablo; Einhorn, Lawrence; Bhatia, Sumeet; Ansari, Rafat; Bechar, Naftali; Koneru, Karuna; Govindan, Ramesh; Wu, Jingwei; Yu, Menggang; Schneider, Bryan; Hanna, Nasser. Journal of Thoracic Oncology. 5(12):2008-2011, December 2010.

Trials in Progress Poster Presentation
PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BR09-22-41
J Sharma, Constantan Yiannoutsou, Noah Hahn, Christopher Sweeney.
Download Poster

Our 2011 Peer-Reviewed Publications

Our peer-reviewed research is truly without peer.

P. Quake Pletcher, Executive Director, Hoosier Oncology Group

Thank you to all the dedicated researchers listed above, as well as, the army of site personnel who make this research possible.

Hoosier oncology group 2011 peer-reviewed publications
No longer is cancer treated with a “one size fits all” approach, but instead, we now use the term Personalized Medicine to refer to individualized cancer treatment plans based on our DNA biomarkers. Scientists are now starting to understand cancer at a molecular level and learning how to turn DNA switches on and off. We now know that we ourselves—as well as our individual biomarkers— affect which drug(s) will be most effective in treating a specific cancer in our bodies.

Hoosier Oncology Group has always been a leader in cancer research and we are proud to continue to lead in the age of personalized medicine. Many of the studies we conduct are oriented toward this new-age research and the results of these studies will be instrumental in improving treatment, and may lead to future discoveries.

The BNK09-138 study, led by Noah Hahn, medical oncologist at the Indiana University Melvin and Bren Simon Cancer Center, represents an important translational opportunity for the Hoosier Oncology Group. Unlike traditional clinical trials that test new drugs with uncertain benefit, the BNK09-138 study focused on the collection of blood and tissue samples from metastatic lung, ovarian, and bladder cancer patients who never received chemotherapy. In addition, blood samples were collected from patients with no prior history of cancer. The samples obtained from BNK09-138 will allow investigators to perform initial studies to identify biomarkers that can be used to identify cancer and predict response to current standard chemotherapy agents. Through such investigations, the BNK09-138 study further supports the Hoosier Oncology Group’s vision to bring true personalized cancer care to individuals in their communities.

The LUN07-130 study is another example of examining the roles and responses of certain biomarkers or proteins to promising new drugs. This study was a phase I trial that investigated two specific biomarkers of patients with recurrent lung cancer. The goal was to determine if the presence of these biomarkers could predict how well the patients would respond to the addition of amrubicin to cyclophosphamide in their treatment plan.

"Goals of cancer research performed by the Hoosier Oncology Group focus not only on improving outcomes of this difficult disease, but also on personalizing therapy for cancer. It is clear we should no longer treat patients as 'one size fits all'. Identifying the markers that will determine patients most likely to benefit from different therapies is of significant value and should be included in all trials, including early phase I trials."

Shadia Jalal, M.D., Assistant Professor of Medicine, Indiana University School of Medicine; Principal Investigator of the LUN07-130 study

Tailored to your DNA

Personalized medicine to provide individualized treatment plans based on your DNA biomarkers.

Scientists are now starting to understand cancer at a molecular level and learning how to turn DNA switches on and off.
Divorced, alone, an empty nester with two girls in college, and he discovers a lump on his neck. Tom Sibert is diagnosed with stage IV Non-Hodgkin’s Lymphoma at the age of 49, only two weeks after the passing of his mother.

Tom soon learns his type of cancer is a slow growing, but hard to kill cancer. Guided by his oncologist, Dr. Andrew Greenspan, Tom hears of a promising new cancer drug on the market coming out of clinical trials called Rituxan®.

Tom undergoes chemotherapy followed by one treatment of Rituxan® per week for four weeks. Rituxan® proves to be a miracle drug that is not only extremely effective, but also has very few side effects. Through the support of friends, church members, and caring oncology nurses, Tom makes a full recovery. He remarks, “If there is anything I learned it is this: you need to let others care about you.”

That was 13 years ago.

Today, at the age of 62, Tom thoroughly enjoys each and every day with his wife of seven years, Cindy, two married daughters and five grandchildren. He is active in his church, he travels, he reads, he cycles and he has plans for the future – a trip to France, a golf outing with the guys.

Though Tom has had several relapses, each time he has been successfully treated with Rituxan, the drug that became available only after being proven as an effective treatment in a clinical trial.

Right: Tom and Cindy
Hoosier Oncology Group first befriended Janie Gordon last year when she directed the Columbus North High School Choir at the 25th Anniversary Gala and spoke of her personal story as a breast cancer survivor. Following the gala, Janie and her students volunteered to perform an annual benefit concert called “Courage to Climb”, with all proceeds earmarked for Hoosier Oncology cancer research. The first annual concert event, held on April 25, 2011, was a great success, raising over $5,000. At the event, Janie Gordon was presented with the 2010 Terry Hoeppner Patient Advocacy Award in recognition of her generosity of spirit and support for cancer research. This award is given annually to an extraordinary individual who epitomizes the “never quit” attitude for which Coach Hep was so well known.

In her own words, Janie expresses her feelings as the award recipient, “I was completely shocked and humbled to receive the prestigious Terry Hoeppner Patient Advocacy Award. As a cancer survivor, and a friend of so many who are struggling now or who have lost their battles, volunteering with our annual “Courage to Climb” concert is a highlight for me and my students each year. It is my hope that we can share this fund-raising and cancer recognition concert with other communities in our region.”

Hoosier Oncology Group is very fortunate to have friends and supporters such as Janie Gordon, and we thank her and all those involved in this wonderful event for being so generous with their time and talents. The next Courage to Climb benefit concert will be held on April 11, 2012, so mark your calendars!

Anyone interested in replicating the Courage to Climb event in their community, please contact Cyndi Burkhardt at 317-921-2050.
The Sandra Turner Excellence in Clinical Research Awards

The Sandra Turner Excellence in Clinical Research Awards were established in 2002 to honor the memory of Sandra Turner, the very first Executive Director of the Hoosier Oncology Group. Each year, the Hoosier Oncology Group selects individuals who exemplify the qualities Sandra possessed and respected in others, such as sustained professional commitment, contribution to the progress of oncology care, and the unflinching touch of compassion. Maura Buckley, Research Compliance Coordinator at the Indiana University Melvin and Bren Simon Cancer Center, was selected as this year’s recipient in recognition of her dedication and commitment to excellence in cancer research.

Maura receives a $1,500 unrestricted educational grant, generously provided by the Fisher Family Fund. Maura in her own words comments on the award, “I was quite surprised to be honored with the Sandra Turner Award this year. I have not yet selected an educational opportunity for which to use the award this year, but hope to pursue something once my schedule is a little less hectic.”

Right: Maura Buckley

This award is given to individuals who possess sustained professional commitment, contribution to the progress of oncology care and the unflinching touch of compassion.
Awards | Recognizing Greatness in Others

George and Sarah Jane Fisher Award

One of our founding fathers, Dr. William B. Fisher, has once again graciously endowed a new award through the Fisher Family Fund to challenge the next generation of cancer researchers. The George and Sarah Jane Fisher Award will be given annually beginning in 2012 to the Indiana University oncology fellow deemed to have made the most significant contribution to clinical or basic science research in collaboration with the Hoosier Oncology Group. Recipients will be selected by key oncology and Hoosier Oncology Group faculty members.

This award will be given to the Indiana University oncology fellow deemed to have made the most significant contribution to clinical or basic science research in collaboration with the Hoosier Oncology Group.
We have audited the accompanying statements of financial position of the Hoosier Oncology Group, Inc. (the "Organization") as of June 30, 2011 and 2010 and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Organization's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Hoosier Oncology Group, Inc. as of June 30, 2011 and 2010, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Crowe Horwath LLP, Indianapolis, Indiana

October 27, 2011

Financials | Report of Independent Auditors

Financials | Statements of Financial Position June 30, 2011 and 2010

ASSETS

<table>
<thead>
<tr>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$2,367,266</td>
</tr>
<tr>
<td>Accounts and grants receivable, net</td>
<td>1,158,635</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>77,407</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>34,471</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$3,637,779</strong></td>
</tr>
</tbody>
</table>

LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th></th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$139,609</td>
<td>$209,091</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>244,352</td>
<td>230,148</td>
</tr>
<tr>
<td>Accrued payroll</td>
<td>80,626</td>
<td>51,928</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td></td>
<td>23,599</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>465,187</strong></td>
<td><strong>514,766</strong></td>
</tr>
<tr>
<td>Net assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>2,989,974</td>
<td>3,099,115</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>182,618</td>
<td>182,618</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>3,172,592</strong></td>
<td><strong>3,281,733</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$3,637,779</strong></td>
<td><strong>$3,796,499</strong></td>
</tr>
</tbody>
</table>
## Financials | Statements of Activities Year Ended June 30, 2011 and 2010

<table>
<thead>
<tr>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>2011 Total</th>
<th>2010 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>External support - research</td>
<td>$2,393,380</td>
<td>$2,393,380</td>
<td>$2,890,320</td>
</tr>
<tr>
<td>Federal research grants</td>
<td>345,206</td>
<td>-</td>
<td>345,206</td>
</tr>
<tr>
<td>Contributions and other grant support</td>
<td>578,345</td>
<td>-</td>
<td>578,345</td>
</tr>
<tr>
<td>Interest income</td>
<td>7,411</td>
<td>-</td>
<td>7,411</td>
</tr>
<tr>
<td>Special Events</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other income</td>
<td>18,815</td>
<td>-</td>
<td>18,815</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td>$3,343,157</td>
<td>-</td>
<td>$3,343,157</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator initiated research</td>
<td>1,713,777</td>
<td>-</td>
<td>1,713,777</td>
</tr>
<tr>
<td>Industry research</td>
<td>417,925</td>
<td>-</td>
<td>417,925</td>
</tr>
<tr>
<td>Government research</td>
<td>561,750</td>
<td>-</td>
<td>561,750</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>$2,693,452</td>
<td>-</td>
<td>$2,693,452</td>
</tr>
<tr>
<td>Supporting services</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration</td>
<td>737,673</td>
<td>-</td>
<td>737,673</td>
</tr>
<tr>
<td>Fundraising</td>
<td>21,173</td>
<td>-</td>
<td>21,173</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>$758,846</td>
<td>-</td>
<td>$758,846</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>$3,452,298</td>
<td>-</td>
<td>$3,452,298</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>$(109,141)</td>
<td>-</td>
<td>$(109,141)</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>$3,099,115</td>
<td>$182,618</td>
<td>$3,281,733</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$2,989,974</td>
<td>$182,618</td>
<td>$3,172,592</td>
</tr>
</tbody>
</table>

## Financials | Statements of Cashflow Years Ended June 30, 2010 and 2011

<table>
<thead>
<tr>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$(109,141)</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash used from operating activities:</td>
<td></td>
</tr>
<tr>
<td>Depreciation</td>
<td>12,444</td>
</tr>
<tr>
<td>Change in assets and liabilities:</td>
<td></td>
</tr>
<tr>
<td>Accounts and grants receivable</td>
<td>319,534</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>(6,299)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>(69,482)</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>14,854</td>
</tr>
<tr>
<td>Accrued payroll</td>
<td>28,698</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(23,599)</td>
</tr>
<tr>
<td><strong>Net cash provided by (used in) operating activities</strong></td>
<td>$166,365</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities</strong></td>
<td></td>
</tr>
<tr>
<td>Purchase of property and equipment</td>
<td>$22,322</td>
</tr>
<tr>
<td>Net cash used in investing activities</td>
<td>$22,322</td>
</tr>
<tr>
<td><strong>Net change in cash and cash equivalents</strong></td>
<td>$144,637</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>$2,222,629</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of year</td>
<td>$2,367,266</td>
</tr>
</tbody>
</table>
Thank you!

Our Contributors

The Hoosier Oncology Group wishes to thank all those who contributed throughout the year to our mission of providing leading research to people within their communities.

We are so fortunate to have many friends and supporters who give of their time, money, services, expertise and other valuable resources to help us fulfill our mission.

PLATINUM LEVEL ($5000 and above)
- Ella Fern Blount
  In Memory of Mr. Alwin Fisher Family Fund

GOLD LEVEL ($2500-5499)
- Tracey Dale, Southern Roofing, Inc.
  In Honor of Patricia Conway Sr., ACO
- Coach Hep Indiana Cancer Challenge
- Robin Zon, Board Member
  In Memory of Alice Zon

SILVER LEVEL ($800-2499)
- Rafat Abonour, Board Member
- Sumeet and Sumeeta Bhatia, Board Member
- Bhatia Family Charitable Fund
- Melissa Caito, Board Member
- William Fisher, Emeritus Board Member
- Wael Harb, Board Member, Horizon Oncology Research
- Charles Fox, Board Member, The Fox Family Trust
- Noah Hahn, Board Member
- Faisal Hammad, Board Member
- Nasser Hanna, Board Member, Pan-Kan Company
- Christopher Lollis, Board Member
- RM Prasad Muthuswamy, Emeritus Board Member
- P. Quade Fletcher, Executive Director
  In Memory of Lucille Hawkins Albert and Keema Schumaker

BRONZE LEVEL ($250-999)
- Drew August
  In Honor of Naomi Harris, M.D.
- Christopher Faulk
  In Memory of Mark Przywarski, M.D.
- Charles Fox, Board Member
- Noah Hahn, Board Member
- Faisal Hammad, Board Member
- Nasser Hanna, Board Member, Pan-Kan Company
- Christopher Lollis, Board Member
- RM Prasad Muthuswamy, Emeritus Board Member
- P. Quade Fletcher, Executive Director
  In Memory of Lucille Hawkins Albert and Keema Schumaker

How You Can Help

You can make a tax-deductible donation toward 21st century cancer research online:
https://co.clickandpledge.com/sp41/default.aspx?w2d=24679

If you are interested in volunteering or becoming an advocate, visit our volunteer webpage at:
www.hoosieroncologysgroup.org/Volunteer-ops.aspx

FRIENDS ($249 and under)
- Barbara Stanbury, La Mode 60
- Larry Sturhill, In Memory of Kendall Sharp
- Melissa Burkhart, In Memory of Kendall Sharp
- Ray Buterin
- Gary Burrell
- Damon Chandler
- Nicholas Conner
- DBA Bookkeeping Today!
- Elaine Halsted
- Sherron Harris
- Veronica Henry
- Katie Jerome
- Edward Miller
- Thomas Mueller
- DBA Miller Insurance Agency
- M. Neuell
- Gary Noles, In Memory of Kendall Sharp
- Gregory Notebalie
- Janell Ovaitt
- Rick Peterson, In Memory of Kendall Sharp
- Christine Pflueger
- Mary Barbara Ream
- Vince Savd, In Honor of Sue Kinman
- Joseph Sheely
- Janette Snyder
- Marsha Sons
- Matthew Souza
- LaTrice Vaughn, Board Member
- Jerry Walker
- H. William Watts
- Watts Family Dentistry
- Pamela Wells-Lego
- Thomas Wilson

The Hoosier Oncology Group also wishes to thank all the dedicated investigators, clinical research site personnel, volunteers and the patients who make our research possible.

In particular, we would like to acknowledge:
- Janie Gordon, for her generosity of time and talent
- Flat Long, for volunteering her editorial expertise towards this annual report
- Long-time volunteer, Ted Stansbury, for his leadership in donor relations and community outreach

*The Hoosier Oncology Group strives to acknowledge each and every contributor accurately. The information above reflects contributions made between July 1, 2010 – June 30, 2011. If the information listed above is incorrect or not inclusive, please contact our offices at 317-921-2050 and ask to speak with donor relations. Thank you for your support!*